Global Health Limited to consider Q2 FY27 results on Nov 3

Global Health Limited will consider its unaudited Q2 FY27 and half-year results for the period ended September 30, 2026, on November 3, following Q1 FY27 healthcare revenue of ₹1,304.05 crore and profit after tax of ₹157.25 crore. The September-quarter figures had not been filed in the information provided before the board meeting.

When will Medanta announce its Q2 FY27 results?

Medanta's board is scheduled to meet on November 3, 2026, to consider and approve unaudited financial results for Q2 FY27 and the half year ended September 30, 2026. The company has also scheduled an earnings call for November 4, with Dr. Naresh Trehan and Chief Financial Officer Yogesh Gupta listed as participants.

The meeting is significant because it will provide the first reported financial update for the July-September quarter. The available information states that the Q2 figures were not filed before the scheduled board meeting. As a result, revenue, profit, margin and volume outcomes for the quarter should not be treated as reported until the company releases its results.

Medanta closed its trading window on October 1, 2026. It will reopen 48 hours after the financial results are declared, in line with the company's stated compliance process under SEBI regulations.

What did Medanta report in Q1 FY27?

Medanta reported consolidated healthcare operating revenue of ₹1,304.05 crore in Q1 FY27, up 26.5% year on year. Total income reached ₹1,326.22 crore for the quarter ended June 30, 2026, which the company described as its highest quarterly total income to date.

Profit after tax was ₹157.25 crore, compared with ₹159.0 crore in the corresponding quarter of the prior year. This represented a 1.1% year-on-year decline despite the stronger revenue base. Reported EBITDA increased 23.5% year on year to ₹315.3 crore, with an EBITDA margin of 23.8%.

The company also provided an adjusted view excluding its ramping Noida facility. On that basis, EBITDA was ₹320.1 crore, up 23.9% year on year, while the EBITDA margin was 25.8%. This disclosure indicates that the newer hospital continued to affect the consolidated operating margin during its expansion phase.

Which operating trends supported the June-quarter performance?

Medanta's Q1 FY27 performance was supported by growth in patient volumes and occupied bed days. In-patient counts rose 27.7% year on year to 60,214, while out-patient encounters increased 34.5% to 1,100,928.

Occupied bed days increased 21.1% year on year to 173,064. The company linked its revenue performance to broad-based clinical-volume growth, while the available material also cited higher occupancy and service-line growth as operational drivers.

The figures show that revenue expansion was accompanied by increased utilisation across hospital operations. However, the Q1 profit comparison also shows that higher activity did not translate into year-on-year PAT growth in the reported quarter, partly alongside the continued ramp-up of the Noida facility.

How does the Noida expansion affect Medanta's financials?

The Noida hospital remains an important element of Medanta's operating and financial context. The company disclosed that EBITDA margin excluding the ramping Noida facility was 25.8% in Q1 FY27, compared with the reported consolidated EBITDA margin of 23.8%.

The difference between these measures reflects the cost of scaling a newer unit before it reaches mature utilisation levels. Medanta has previously identified newer hospitals, including Noida, Lucknow and Patna, as growth engines, while noting the potential for volume growth in the expanding network.

For investors, the Q2 release will be relevant for assessing whether growth in patient activity and hospital capacity is continuing. The disclosed Q1 figures provide a base for comparison, but no September-quarter operational or financial data were available in the material provided.

What other corporate developments were disclosed before the meeting?

Medanta allotted 2,750 ESOP shares to the GHL Employees Welfare Trust, increasing its paid-up capital to ₹53,77,55,064. The company also disclosed that Dr. Pankaj Dhamija resigned as Hospital Director of the Gurugram unit with effect from October 30, 2026, following mutual agreement.

Separately, Global Health Limited filed its FY26 Business Responsibility and Sustainability Report on August 21, 2026. For FY26, consolidated total income rose 19.6% to ₹4,508.9 crore and profit after tax increased 15.1% to ₹554.1 crore. EBITDA before ESOP expenses was ₹1,056.0 crore, with a margin of 23.4%.

Conclusion

The November 3 board meeting is the immediate event for Medanta shareholders because it will formally establish Q2 FY27 and first-half financial performance. The reported Q1 base showed strong growth in healthcare revenue, EBITDA and patient volumes, while PAT was marginally lower year on year and the Noida facility continued to influence consolidated margins.

Investors will watch the November 4 earnings call for management's comments on capacity utilisation, the ramp-up of newer hospitals and the relationship between revenue growth and margins. The company has not disclosed Q2 FY27 figures in the supplied information ahead of the board's decision.